Search

Displaying results 1941 - 1950 of 4600 in total
  1. Drug

    Patritumab deruxtecan

    go.drugbank.com/drugs/DB21996
    Investigational

    Patritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).

    Synonyms: Anti-her3 antibody-drug conjugate u3 1402
  2. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.

  3. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood.

  4. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

  5. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known … By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease.

  6. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  7. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, ...

  8. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig heavy chain V-III region BUR
  9. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL.

  10. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema.